Arecor to re­tain In­hi­brx roy­al­ties in wake of Sanofi ac­qui­si­tion

The com­pa­ny that de­vel­oped the tech­nol­o­gy be­hind Sanofi’s pur­chase of In­hi­brx said that roy­al­ty oblig­a­tions won’t change with the ac­qui­si­tion.

Arecor, a Cam­bridge, UK start­up, will re­tain roy­al­ties to IN­BRX-101, Sanofi’s pri­ma­ry ac­qui­si­tion tar­get, fol­low­ing a li­cens­ing agree­ment be­tween Arecor and In­hi­brx from 2020, ac­cord­ing to a press re­lease. The an­nounce­ment comes af­ter Arecor re­ceived a mile­stone pay­ment from In­hi­brx last No­vem­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER